APYX MEDICAL CORPORATION APPOINTS MATTHEW HILL AS CHIEF FINANCIAL OFFICERBy ApyxMedical|2025-12-12T18:13:02-05:00November 28, 2023|
APYX MEDICAL CORPORATION ANNOUNCES NEW DEBT FACILITY WITH PERCEPTIVE ADVISORSBy ApyxMedical|2025-12-12T18:58:20-05:00November 9, 2023|
APYX MEDICAL CORPORATION REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND UPDATES FULL YEAR 2023 FINANCIAL OUTLOOKBy ApyxMedical|2025-12-12T18:58:55-05:00November 9, 2023|
APYX MEDICAL CORPORATION TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES IN NOVEMBERBy ApyxMedical|2025-12-12T18:59:25-05:00November 7, 2023|
APYX MEDICAL CORPORATION TO RELEASE THIRD QUARTER OF FISCAL YEAR 2023 FINANCIAL RESULTS ON NOVEMBER 9, 2023By ApyxMedical|2025-12-12T18:59:53-05:00October 2, 2023|
APYX MEDICAL CORPORATION REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND REAFFIRMS FULL YEAR 2023 FINANCIAL OUTLOOKBy ApyxMedical|2025-12-12T19:00:21-05:00August 10, 2023|
APYX MEDICAL CORPORATION TO RELEASE SECOND QUARTER OF FISCAL YEAR 2023 FINANCIAL RESULTS ON AUGUST 10, 2023By ApyxMedical|2025-12-12T19:00:50-05:00June 29, 2023|
APYX MEDICAL CORPORATION ANNOUNCES FDA 510(K) CLEARANCE FOR THE RENUVION MICRO HANDPIECEBy ApyxMedical|2025-12-12T19:01:32-05:00June 14, 2023|
APYX MEDICAL CORPORATION REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND UPDATES FULL YEAR 2023 FINANCIAL OUTLOOKBy ApyxMedical|2025-12-12T19:02:02-05:00May 11, 2023|
RENUVION RECEIVES FDA CLEARANCE FOR SPECIFIC USE AFTER LIPOSUCTIONBy ApyxMedical|2025-12-12T19:02:46-05:00May 2, 2023|
APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION FOR COAGULATION OF SUBCUTANEOUS SOFT TISSUES FOLLOWING LIPOSUCTION FOR AESTHETIC BODY CONTOURINGBy ApyxMedical|2025-12-12T19:03:25-05:00April 28, 2023|
APYX MEDICAL CORPORATION TO RELEASE FIRST QUARTER OF FISCAL YEAR 2023 FINANCIAL RESULTS ON MAY 11, 2023By ApyxMedical|2025-12-12T19:03:58-05:00April 5, 2023|
RENUVION WINS ADDY AWARD FOR #THISISME CAMPAIGNBy ApyxMedical|2025-12-12T19:04:30-05:00March 27, 2023|
APYX MEDICAL CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS; INTRODUCES FULL YEAR 2023 FINANCIAL OUTLOOKBy ApyxMedical|2025-12-12T19:05:09-05:00March 16, 2023|
APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION TO COAGULATE AND CONTRACT SOFT TISSUES, INCLUDING SUBCUTANEOUS TISSUE, WHERE NEEDEDBy ApyxMedical|2025-12-12T19:05:39-05:00February 27, 2023|
